Antiepileptic drug use by pregnant women enrolled in Florida Medicaid

Neurology

Volumn 84, Issue 9, 2015, Pages 944-950

  Wen, Xuerong ^a   Meador, Kimford J ^c   Hartzema, Abraham ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FOLIC ACID; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADULT; ANXIETY; ARTICLE; BIPOLAR DEPRESSION; COHORT ANALYSIS; DRUG USE; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; MENTAL DISEASE; MIGRAINE; MONOTHERAPY; PREGNANCY; PREGNANT WOMAN; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THERAPY; UNITED STATES; PREGNANCY COMPLICATIONS; YOUNG ADULT;

ADULT; ANTICONVULSANTS; COHORT STUDIES; EPILEPSY; FEMALE; FLORIDA; HUMANS; MEDICAID; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84924163241     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001304     Document Type: Article

References (40)

1. Samren EB, van Duijn CM, Christianens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739-746.
2. Kaneko S, Kondo T. Antiepileptic agents and birth defects: incidence, mechanisms and prevention. CNS Drugs 1995;3:41-55.
3. Tomson T. Which drug for the pregnant woman with epilepsy? N Engl J Med 2009;360:1667-1669.
4. Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988;29:459-467.
5. Friis ML. Facial clefts and congenital heart defects in children of parents with epilepsy: genetic and environmental etiologic factors. Acta Neurol Scand 1989;79:433-459.
6. Tomson T, Battino D, French J, et al. Antiepileptic drug exposure and major congenital malformations: the role of pregnancy registries. Epilepsy Behav 2007;11:277-282.
7. Pennell PB. Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest? Epilepsia 2008;49(suppl 9):43-55.
8. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004;61:673-678.
9. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010;362:2185-2193.
10. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-198.
11. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006;67:407-412.
12. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-965.
13. Meador KJ, Pennell PB, Harden CL, et al; for the HOPE Work Group. Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology 2008;71:1109-1117.
14. Meador KJ, Baker GA, Browning N, et al; for the NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360:1597-1605.
15. Meador KJ, Baker GA, Browning N, et al; for the NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013;12:244-252.
16. Tomson T, Battino D, Bonizzoni E, et al EURAP Study Group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-617.
17. Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 2014;85:1029-1034.
18. Hernández-Díaz S, Smith CR, Shen A, et al North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-1699.
19. Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland Epilepsy and Pregnancy Registers. Neurology 2013;80:400-405.
20. Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011;305:1996-2002.
21. Florida Department of Children and Families. Family-related Medicaid programs fact sheet. Available at: http://www.dcf.state.fl.us/programs/access/docs/fammedfactsheet.pdf. Accessed August 17, 2014.
22. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989;129:837-849.
23. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995;142:1103-1112.
24. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-2451.
25. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-1132.
26. Simmons M, Thompson D, Graham C. An evaluation of the healthy start prenatal screen. Available at: http://www.floridahealth.gov/programs-and-services/childrens-health/healthy-start/healthy-start-docs/prenatal-screen-eval.pdf. Accessed December 13, 2012.
27. Eworuke E, Hampp C, Saidi A, Winterstein AG. An algorithm to identify preterm infants in administrative claims data. Pharmacoepidemiol Drug Saf 2012;21:640-650.
28. Raebel MA, Ellis JL, Andrade SE. Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. Pharmacoepidemiol Drug Saf 2005;14:829-836.
29. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398-407.
30. Pearl M, Wier ML, Kharrazi M. Assessing the quality of last menstrual period date on California birth records. Paediatr Perinat Epidemiol 2007;21(suppl 2):50-61.
31. Northam S, Knapp TR. The reliability and validity of birth certificates. J Obstet Gynecol Neonatal Nurs 2006;35:3-12.
32. Salemi JL, Tanner JP, Block S, et al. The relative contribution of data sources to a birth defects registry utilizing passive multisource ascertainment methods: does a smaller birth defects case ascertainment net lead to overall or disproportionate loss? J Registry Manag 2011;38:30-38.
33. Florida Department of Health. Live Births: Vital Statistics Annual and Provisional Reports, 2009. Available at: http://www.flpublichealth.com/VSBOOK/pdf/2009/Births.pdf. Accessed August 5, 2014.
34. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004;93:174-176.
35. Battino D, Tomson T, Bonizzoni E, et al EURAP Study Group. Seizure control and treatment changes in pregnancy: observations from the EURAP Epilepsy Pregnancy Registry. Epilepsia 2013;54:1621-1627.
36. Bobo WV, Davis RL, Toh S, et al. Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study. Paediatr Perinat Epidemiol 2012;26:578-588.
37. Meador KM, Penovich P, Baker GA, et al; for the NEAD Study Group. Antiepileptic drug use in women of child-bearing age. Epilepsy Behav 2009;15:339-343.
38. Wen X, Meador KJ, Winterstein AG, Hartzema AG. Utilization of antiepileptic drugs in Florida Medicaid women with epilepsy of childbearing age. Pharmacoepidemiol Drug Saf 2012;21(suppl 3):322.
39. Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;50:1237-1246.
40. U.S. Food and Drug Administration. FDA Drug Safety Communication: risk of oral clefts in children born to mothers taking Topamax (topiramate). Available at: http://www.fda.gov/drugs/drugsafety/ucm245085.htm. Accessed March 16, 2014.